Search results
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 2 days agoNotable data include an oral presentation on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), which evaluated lenvatinib (LENVIMA®), the orally ...
Director Julie Smith Sells 27,280 Shares of Exelixis Inc (EXEL)
GuruFocus.com via Yahoo Finance· 1 day agoThe company is known for its product Cabometyx, which is used in the treatment of various forms of...
Nimbus reports positive data from Phase I/II solid tumour therapy trial
Clinical Trials Arena via Yahoo Finance· 1 day agoAccording to the results, 16.7% of response-evaluable patients experienced clinical benefits from...
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at...
WKBN 27 Youngstown· 2 days agoOn May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal
ASCO Meeting News Research News and Press Releases
Newswise· 2 days agoNewswise - ASCO Meeting News: ASCO Meeting News Page 1
Ipilimumab, a Pioneer Breakthrough in Cancer Treatment
Forbes· 5 days agoIn 2011, the first in a new generation of anticancer drugs called checkpoint inhibitors was...
Kidney Cancer Immunotherapy Response Linked to Signature Reflecting HLA, Tumor Immune Activity
GenomeWeb News· 4 days agoResearchers found an immune checkpoint blockade response signature in renal cell carcinoma that reflects tumor immune activity influenced by human leukocyte antigen features.
Is CRISPR Therapeutics a Millionaire Maker?
Motley Fool via Yahoo Finance· 3 days agoThe company also has other high-impact clinical programs in later stages of development which are intended to treat conditions like renal cell ...
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Zacks via Yahoo Finance· 3 days agoPer BMY, this is the first phase III study of the subcutaneous formulation of nivolumab to evaluate...
Natixis Advisors L.P. Cuts Holdings in Exelixis, Inc. (NASDAQ:EXEL)
ETF DAILY NEWS· 6 days agoNatixis Advisors L.P. lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent Form 13F filing ...
